Latest Articles and Analysis

For a long time, I thought advocacy meant surviving the next appointment. I thought it meant learning how to explain my pain better, how to prepare for another referral visit, how to justify why I...

Editor's Note: This article was originally published on April 10, 2026, by Lupus Colorado and is republished here with permission. The Patient Affordability Roundtable discussed in this piece was...

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

Break Up Big Medicine Act would force structural separation of insurers, PBMs, and pharmacies.

Q1 2026 Watch: HCV/HIV co-infection treatment access under evolving federal and state policies.

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

Enhanced ACA subsidies expired Jan 1; Senate framework proposes two-year extension with restrictions.

World AIDS Day honors resilience of HIV advocates and communities resisting policy failures and system barriers to care.

Personal narrative on becoming an HIV advocate and the gratitude found in fighting for healthcare access from lived experience.

Senate HELP Committee hearing reveals how 340B drug program expansion reflects hospital business strategy rather than patient benefit.

Q4 2025 Watch monitoring HCV treatment access and federal initiatives including Cure Hepatitis C Act.

Government shutdown disrupts grant payments to community health centers and crisis service providers, threatening vulnerable population access.

Trump administration's revocation of competition executive order accelerates healthcare consolidation and threatens patient access.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

Impending HIV care crisis results from Medicaid work requirements, federal funding cuts, and healthcare system fragmentation.

Healthcare policy equality forms the foundation for LGBTQ+ liberation and health equity in prevention and treatment access.

Q2 2025 Watch monitoring HCV and HIV treatment access through ADAPs, Medicaid, and federal assistance.

Federal spending cuts disproportionately impact vulnerable populations relying on safety-net programs and community health services.